Last reviewed · How we verify
cephalexin, or levofloxacin, or clindamycin
Cephalexin is a beta-lactam antibiotic that inhibits cell wall synthesis in bacteria.
Cephalexin is a beta-lactam antibiotic that inhibits cell wall synthesis in bacteria. Used for Uncomplicated urinary tract infections, Skin and skin structure infections.
At a glance
| Generic name | cephalexin, or levofloxacin, or clindamycin |
|---|---|
| Also known as | Kelfex, Levaquin, Cleocin |
| Sponsor | Vanderbilt University Medical Center |
| Drug class | cephalosporin |
| Target | penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Cephalexin works by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, resulting in the disruption of the cell wall synthesis and ultimately leading to bacterial cell death.
Approved indications
- Uncomplicated urinary tract infections
- Skin and skin structure infections
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. (PHASE3)
- Short-Term Use of Antibiotics and Adherence Level (NA)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: